Sanofi sues Merck for infringing Lantus patents
Sanofi is taking Merck & Co to court claiming that the firm has infringed 10 patents covering its best-selling insulin glargine products Lantus and Lantus SoloStar.
Read More
Tag: Lantus
Novo’s Tresiba beats Sanofi’s Lantus on reducing hypoglycaemia
Novo Nordisk has showcased new data from two Phase IIIb trials showing that diabetes patients treated with Tresiba experienced significantly lower rates of several types of hypoglycaemia than those using Sanofi’s Lantus.
Read More
- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
